Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Stage I Breast Cancer
Interventions: BIOLOGICAL: Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination
Sponsor: Fundacio Clinic Barcelona
Collaborators: SOLTI Breast Cancer Research Group|Roche Pharma AG